Tofersen Fails to Slow SOD1-ALS in VALOR Trial, But Hopeful Trends Seen
Tofersen, an experimental treatment for amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, failed to significantly…
Articles by Marisa Wexler, MS
Neuturin Protein in Muscles May Be of ‘Therapeutic Value’ in ALS
A signaling protein called neurturin promotes the development of muscles with greater endurance, leading to better exercise performance and…
NIH Grant Supports ALS Trial Into Brain Signals Controlling Movement
A five-year National Institutes of Health (NIH) grant worth $2.4 million will support an Emory University researcher’s use of artificial intelligence (AI)…
Phase 3 Trial of Masitinib Again Enrolling ALS Patients in Norway
A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical…
I AM ALS Expanding Efforts Into Research, Patient Support
I AM ALS, a nonprofit dedicated to helping people affected by amyotrophic lateral sclerosis (ALS), is expanding its…
Defects in Cholesterol Metabolism, Due to TDP-43 Protein, Tied to ALS
Defects in cholesterol metabolism may account for some of the neurological damage that occurs in amyotrophic lateral sclerosis (ALS)…
Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show
Treatment with the investigational oral therapy masitinib can extend lifespan when given early in the course of amyotrophic…
Childhood Form of ALS Identified, Linked to SPLTC1 Mutations
A previously unknown form of amyotrophic lateral sclerosis (ALS) — one with onset during childhood — is caused by mutations…
Nearly $12M Grant Will Fund ALS Cell Therapy Trial at Cedars-Sinai
Cedars-Sinai Medical Center, in California, has been awarded an $11.99 million grant to support a clinical trial that will test…
Rare 2030 Action Campaign Pushing for European Plan for Rare Diseases
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…